Drug Profile
Research programme: intranasal sedatives - MedPharm/OptiNose
Alternative Names: OPT-1045Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MedPharm; OptiNose AS
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Insomnia; Panic disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in Europe (Intranasal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Insomnia in Europe (Intranasal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Panic-disorder in Europe (Intranasal, Spray)